Lean Body Mass and Side Effects in Patients With Lymphoma

NCT ID: NCT04698616

Last Updated: 2021-01-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

141 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-09

Study Completion Date

2021-03-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose is to investigate the relationship between the dose of chemotherapeutic agents per kilogram of lean body mass (LBM) and the development of side effects induced by chemotherapy in patients with lymphoma. Secondarily, the maximum tolerable dose of chemotherapeutics (MTD), patients' quality of life (QOL), nutritional status and physical activity during the course of treatment are estimated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Malignant lymphoma patients

Identification of the patients who are/are not dose-reduced due to chemotherapy, and then look at the body composition in connection with this.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients receiving myelosuppressive treatment for malignant lymphoma assessed by the investigator.
* Legal of age

Exclusion Criteria

* ECOG Performance Status ≥2
* People who cannot speak and understand Danish
* Pregnant and breastfeeding
* Dementia
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jens Rikardt Andersen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jens Rikardt Andersen

Sponsor - Investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jens R Andersen, MD,MPA

Role: STUDY_CHAIR

University of Copenhagen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Copenhagen

Copenhagen, Frederiksberg, Denmark

Site Status COMPLETED

Sjællands Universitetshospital, Hæmatologisk Afdeling H60

Roskilde, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Christian Bjørn Poulsen, MD, PhD

Role: CONTACT

+45 47324809

Jens R Andersen, MD,MPA

Role: CONTACT

+4523346654

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Christian Bjørn Poulsen, MD,PhD

Role: primary

+45 47324809

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SJ-823

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Maintenance Hormonal Therapy and DLBCL
NCT06355401 NOT_YET_RECRUITING PHASE2/PHASE3